Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antisense and RNAi Therapeutics Market

Antisense and RNAi Therapeutics Market Share

Report ID: GMI9517
Published Date: May 2024
Report Format: PDF

Download Free Sample

Antisense and RNAi Therapeutics Market Share

The antisense and RNAi therapeutics industry is fragmented. Although major market players hold significant influence, smaller companies and research institutions also play a vital role in advancing and bringing these therapies to market. Established players have extensive pipelines, substantial research capabilities, and established partnerships with other biotechnology and pharmaceutical companies. Small companies are majorly involved in the researching and developing RNAi and antisense therapeutics focusing on niche areas or specific diseases, which has contributed to the overall diversity in the market.

Antisense and RNAi Therapeutics Market Companies

Prominent players operating in the antisense and RNAi therapeutics industry include:

Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Arrowhead Pharmaceuticals, Inc.
Benitec Biopharma Inc.
BioNTech SE.
CRISPR Therapeutics
GlaxoSmithKline plc
Ionis Pharmaceuticals, Inc.
Novartis AG
OliX Pharmaceuticals, Inc.
Orna Therapeutics, Inc.
Percheron Therapeutics Ltd.
Sanofi
Sarepta Therapeutics, Inc.
Silence Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The antisense and RNAi therapeutics market size was valued at USD 4.4 billion in 2023 and will register 18.2% CAGR from 2024 – 2032, driven by the increasing prevalence of neurodegenerative and genetic disorders.

The RNA interference technology segment in the market held 62.4% share in 2023 and will expand rapidly through 2032, owing to its broader application spectrum compared to antisense RNA, making it more versatile and applicable.

North America antisense and RNAi therapeutics market accounted for 42.1% share in 2023 and is predicted to reach USD 8.2 billion by 2032, driven by the presence of large number of pharmaceutical manufacturers in the country offering advanced treatment options.

Alnylam Pharmaceuticals, Inc, Arbutus Biopharma, Arrowhead Pharmaceuticals, Inc, Benitec Biopharma Inc, BioNTech SE, CRISPR Therapeutics, GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc, Novartis AG, OliX Pharmaceuticals, Inc, Orna Therapeutics, Inc, and Percheron Therapeutics Ltd.